Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Oncolytic Probiotics with Molecular Pili for Solid Tumor Therapy.

  • 2026-02-03
  • Advanced science (Weinheim, Baden-Wurttemberg, Germany) 13(19)
    • Haodong Ge
    • Chengsheng Ding
    • Xiao Yang
    • Si Gao
    • Changjie Yang
    • Yuchen Hou
    • Hongye Wang
    • Linke Bian
    • Hao Zhong
    • Yifan Qu
    • Luyang Zhang
    • Junjun Ma
    • Zhengwei Cai
    • Wenguo Cui
    • Minhua Zheng

Study Design

Population
mouse models of colorectal cancer and melanoma
Methods
selected a probiotic Lactobacillus rhamnosus (LR), designed molecular pili (MP) targeting collagen-rich solid tumors and modified them into LRs via chemical coupling (LR@MP); in mouse models, LR@MP was given at a safe dose of 4 × 10^5 CFU
Cell therapy and oncolytic viruses have emerged as promising cancer treatments but face significant challenges in solid tumors due to immune suppression and gene-related toxicities. Here, we selected a probiotic Lactobacillus rhamnosus (LR) that appears to exert oncolytic activity by inducing massive calcium influx, which subsequently triggers a lethal ROS burst in tumor cells. To reduce systemic toxicity and enhance oncolytic efficacy at the tumor site, we designed molecular pili (MP) targeting collagen-rich solid tumors and modified them into LRs via chemical coupling (LR@MP). In mouse models of colorectal cancer and melanoma, LR@MP increased intratumoral accumulation by two times and enhanced bacterial clearance from peripheral tissues. At a safe dose of 4 × 105 CFU, LR@MP inhibited 60%-80% of tumor growth. This dual-optimization strategy provides a new approach for next-generation in vivo therapies and warrants further preclinical evaluation.

Research Insights

Back to top